Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON
  1. Home
  2. Azioni
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. Notizie
  7. Altre lingue
    OPS   CA6838231083

OPSENS INC.

(OPS)
Prezzo in differita. Tempo differito Toronto Stock Exchange - 26/10 23:00:00
3.03 CAD   +3.06%
21/09OPSENS INC.: Raymond James mantiene la raccomandazione Buy
MM
02/02OPSENS INC.: Raymond James è per il Buy
MM
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su OPSENS INC.
13/10OPSENS: Says "Successfully Treats" First Patients in Human Clinical Study for TAVR Proced..
13/10OPSENS: Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
13/10OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
29/09OPSENS: to Present at the Lytham Partners Fall 2021 Investor Conference
20/09OPSENS: Receives Health Canada Approval to Initiate First In-Man Clinical Study For Its S..
20/09OPSENS: Receives Approval from Health Canada to Initiate First In-Man Clinical Study for ..
20/09OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for..
08/09OPSENS: Appoints Lori Chmura to its Board of Directors
08/09Opsens Inc. Appoints Lori Chmura to Board of Directors
13/07Opsens Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2021
13/07OPSENS: Reports Q3 Loss Per Share of $0.01, Below Forecast
13/07OPSENS BRIEF: Q3 Basic and Diluted Loss Per Share $0.01 Vs Forecast $0.00 As Per Capital ..
13/07OPSENS: Announces Third Quarter Fiscal 2021 Record Financial Results
13/07NORTH AMERICAN MORNING BRIEFING: Investors Gear -2-
07/07OPSENS: to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesd..
16/06OPSENS: Gets Funding Support to Jointly Develop Optical-Based Fuel Monitoring System For ..
16/06OPSENS: Receives Funding Support to Jointly Develop an Optical-Based Fuel Monitoring Syst..
09/06OPSENS: will Participate and Present at two Investment Conferences - Lytham Partners and ..
13/05OPSENS: to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global He..
21/04UPDATE: OpSens, Cathmedical Cardiovascular Enter Partnership; OpSens Edges Up 5.3%
21/04OPSENS: Cathmedical Cardiovascular Enter Partnership; Edges Up 5.6%
21/04OPSENS: Integrates its OptoWire's dPR and FFR Algorithms Within Cathmedical Cardiovascula..
21/04OpSens Integrates its OptoWire's dPR and FFR Algorithms Within Cathmedical Cardiovascul..
14/04Opsens Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2021
14/04OPSENS: Announces Second Quarter Fiscal 2021 Financial Results and Record FFR and dPR Rev..
07/04OPSENS: Awarded Innovative Technology Contract by Vizient for OptoWire III
07/04OpSens Inc. Receives Innovative Technology Contract by Vizient for OptoWire III
06/04OPSENS: to Host Second Quarter Fiscal Year 2021 Financial Results Conference Call on Wedn..
22/03OPSENS: to Present at Lytham Partners Spring 2021 Investor Conference
25/02OPSENS: Announces Closing of $28.75 Million Bought Deal Public Offering Including $3.75 M..
18/02OPSENS: Obtains CE Marking for the OptoWire III
18/02Opsens Inc. Obtains CE Marking for the OptoWire III
08/02OPSENS: Fiber Optic Sensing Technology Selected For International Thermonuclear Experimen..
08/02OPSENS: Fiber Optic Sensing Technology Selected for the International Thermonuclear Exper..
05/02UPDATE: Opsens Falls 7% as Launches $25 Million Bought Deal Offering
05/02OPSENS: Launches $25 Million Bought Deal Offering
05/02OPSENS: Announces $25 Million Bought Deal Offering
13/01Opsens Inc. Reports Earnings Results for the First Quarter Ended November 30, 2020
13/01OPSENS: Near 52 Week Highs As Reports Q1 EPS $0.01
13/01OPSENS: Announces First Quarter Fiscal 2021 Financial Results
06/01OPSENS: to Host First Quarter Fiscal Year 2021 Financial Results Conference Call on Wedne..
2020OPSENS: to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2020
2020OPSENS: Reports Q4 Net Income of $0.6 Million
2020OPSENS: Earnings Flash (OPSSF) OPSENS Posts Q4 Revenue $7.6M
2020OPSENS: Announces Fourth Quarter and Fiscal Year 2020 Financial Results
2020OPSENS: Recognized as One of the Fastest-Growing Company in North America on Deloitte's 2..
2020OPSENS: to Host Year-End Update Conference Call on Thursday, November 19, 2020
2020OPSENS: Awarded contract by major u.s. group purchasing organization
2020OPSENS: Awarded Contract by Major U.S. Group Purchasing Organization
2020Opsens Inc. Wins Contract by Major U.S. Group Purchasing Organization
2020OPSENS: to Present at Lytham Partners Virtual Investor Growth Conference
2020Opsens Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2020
2020OPSENS: Announces Result for Q3 2020
2020OPSENS: 100,000 Cases Performed with the OptoWire
2020C-SUITE AT THE OPEN: Louis Laflamme, Chief Executive Officer, OpSens Inc., tells his Comp..
2020Opsens Inc. Reports Earnings Results for the Second Quarter Ended February 29, 2020
2020OPSENS: Announces Q2 2020 Results
2020OPSENS: continues to supply essential cardiovascular solutions to patients around the wor..
2020OPSENS: provides operational update - OpSens continues to supply essential cardiovascular..
2020Opsens Inc. Provides Business Update in Light of Recent Action Taken by the Province of..
2020OPSENS: Election Results for the Board of Directors
2020OPSENS: Receives FDA Approval of Optowire III
2020Opsens Receives FDA Approval of Optowire III
2020OPSENS: Announces Q1 2020 Results
2020Opsens Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019
2019Opsens Inc. Receives dPR Clearance from the FDA
2019OPSENS: Receives dPR Clearance from the FDA
2019Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2019
2019Opsens Inc. Announces the World's First Clinical Use of the OptoWire III
2019Opsens Announces Entry into Structural Heart Market
2019Opsens Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019
2019Opsens Inc. Enters into Supply Agreement with Abiomed, Inc. for Impella Cp® Heart Pump
2019Opsens Inc. Appoints Alan Milinazzo as Executive Chairman of the Board of Directors
2019Opsens Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2019
1  2Pross.